INS and Hypoglycemia: TAK-875 is a selective GPR40 agonist that improves glycemic control in T2DM patients by potentiating postprandial insulin secretion in a glucose dependent manner with a minimal risk for hypoglycemia (Kaku, 2013; Yabuki et al., 2013).